A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia
- PMID: 21502541
- DOI: 10.1182/blood-2010-10-313908
A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia
Abstract
Romiplostim, a thrombopoietin-mimetic peptibody, increases and maintains platelet counts in adults with immune thrombocytopenia (ITP). In this first study of a thrombopoietic agent in children, patients with ITP of ≥ 6 months' duration were stratified by age 1:2:2 (12 months-< 3 years; 3-< 12 years; 12-< 18 years). Children received subcutaneous injections of romiplostim (n = 17) or placebo (n = 5) weekly for 12 weeks, with dose adjustments to maintain platelet counts between 50 × 10(9)/L and 250 × 10(9)/L. A platelet count ≥ 50 × 10(9)/L for 2 consecutive weeks was achieved by 15/17 (88%) patients in the romiplostim group and no patients in the placebo group (P = .0008). Platelet counts ≥ 50 × 10(9)/L were maintained for a median of 7 (range, 0-11) weeks in romiplostim patients and 0 (0-0) weeks in placebo patients (P = .0019). The median weekly dose of romiplostim at 12 weeks was 5 μg/kg. Fourteen responders received romiplostim for 4 additional weeks for assessment of pharmacokinetics. No patients discontinued the study. There were no treatment-related, serious adverse events. The most commonly reported adverse events in children, as in adults, were headache and epistaxis. In this short-term study, romiplostim increased platelet counts in 88% of children with ITP and was well-tolerated and apparently safe. The trial was registered with http://www.clinicaltrials.gov as NCT00515203.
Comment in
-
Thrombopoiesis: new ITP paradigm?Blood. 2011 Jul 7;118(1):1-2. doi: 10.1182/blood-2011-05-351700. Blood. 2011. PMID: 21737604 No abstract available.
Similar articles
-
Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).Pediatr Blood Cancer. 2015 Feb;62(2):208-213. doi: 10.1002/pbc.25136. Epub 2014 Oct 24. Pediatr Blood Cancer. 2015. PMID: 25345874 Free PMC article. Clinical Trial.
-
Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.Lancet. 2016 Jul 2;388(10039):45-54. doi: 10.1016/S0140-6736(16)00279-8. Epub 2016 Apr 18. Lancet. 2016. PMID: 27103127 Clinical Trial.
-
Romiplostim: a review of its use in immune thrombocytopenia.Drugs. 2012 Feb 12;72(3):415-35. doi: 10.2165/11208260-000000000-00000. Drugs. 2012. PMID: 22316355 Review.
-
Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.Int J Hematol. 2011 Jul;94(1):71-80. doi: 10.1007/s12185-011-0886-8. Epub 2011 Jun 25. Int J Hematol. 2011. PMID: 21706145 Clinical Trial.
-
Romiplostim in chronic immune thrombocytopenic purpura.Clin Ther. 2009 Sep;31(9):1887-907. doi: 10.1016/j.clinthera.2009.09.013. Clin Ther. 2009. PMID: 19843480 Review.
Cited by
-
Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.Pediatr Blood Cancer. 2016 Aug;63(8):1407-13. doi: 10.1002/pbc.26003. Epub 2016 May 2. Pediatr Blood Cancer. 2016. PMID: 27135461 Free PMC article.
-
Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis.Oncotarget. 2017 Dec 19;9(6):7112-7125. doi: 10.18632/oncotarget.23487. eCollection 2018 Jan 23. Oncotarget. 2017. PMID: 29467954 Free PMC article.
-
Sequential Use of Romiplostim after Eltrombopag for Refractory Thrombocytopenia in Hydrocarbon-Induced Myelodysplasia.Int J Angiol. 2021 Sep 3;33(4):318-321. doi: 10.1055/s-0041-1726366. eCollection 2024 Dec. Int J Angiol. 2021. PMID: 39502356 Free PMC article.
-
Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision.Int J Hematol. 2020 Mar;111(3):329-351. doi: 10.1007/s12185-019-02790-z. Epub 2020 Jan 2. Int J Hematol. 2020. PMID: 31897887 Free PMC article. No abstract available.
-
Diagnosis and management of autoimmune cytopenias in childhood.Pediatr Clin North Am. 2013 Dec;60(6):1489-511. doi: 10.1016/j.pcl.2013.08.009. Epub 2013 Oct 5. Pediatr Clin North Am. 2013. PMID: 24237984 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical